Impact of Mirabegron Administration on the Blood Pressure and Pulse Rate in Patients with Overactive Bladder

• Material Type: 博士論文
• Title: Impact of Mirabegron Administration on the Blood Pressure and Pulse Rate in Patients with Overactive Bladder
• Author/Editor: 伊藤, 秀德
• Author Heading: 伊藤, 秀德
• Publication, Distribution, etc.: MDPI
• Publication Date: 2023-03-20
• Publication Date (W3CDTF): 2023-03-20
• Alternative Title: 過活動膀胱患者におけるミラベグロン投与前後の血圧や脈拍数に対する影響
• Periodical title: Medicina
• No. or year of volume/issue: 58 6
• Volume: 58
• Issue: 6
• Pages: 825-
• ISSN (Periodical Title): ISSN : 1648-9144
• Degree grantor/type: Nagasaki University (長崎大学)
• Date Granted: 2023-03-20
• Dissertation Number: 甲医歯薬第1484号
• Degree Type: 博士(医学)
• Text Language Code: eng
• Subject Heading: blood pressure; pulse rate; mirabegron; overactive bladder
• Target Audience: 一般
• Note (General): Background and Objectives: To determine changes in the blood pressure (BP) and pulse rate (PR) before and after the administration of mirabegron in real-world clinical practice for patients with overactive bladder (OAB). Materials and Methods: This study was conducted in patients newly diagnosed with OAB. Before and 12 weeks after mirabegron treatment, we evaluated the effects on BP and PR. An overall examination was conducted, and the patients were divided into two groups according to their age: a young group (<65 years old) and an old group (≥65 years old). Results: A total of 263 patients were enrolled in this study. In the overall and intragroup comparisons, the systolic BP (SBP) did not change significantly after mirabegron administration. However, an increase in SBP of ≥10 mmHg was observed in 53 (20.2%), 4 (7.4%), and 49 (23.4%) in the entire group, young group, and old group, respectively (p = 0.009). Regarding diastolic BP, a significant decrease after the treatment was detected in entire (71.2 ± 11.4 versus 69.8 ± 10.7 mmHg; p = 0.041) and old patients (71.5 ± 10.6 versus 69.5 ± 10.2 mmHg; p = 0.012). There was no significant change in PR in our study population. Further examination using a propensity match score revealed that age was the risk factor for the increase in SBP after mirabegron administration. Conclusions: Mirabegron does not have any adverse effects on BP and PR. However, since some patients in this study had elevated SBP after administration, we suggest regular BP monitoring during mirabegron treatment.; 長崎大学学位論文 学位記番号:博(医歯薬)甲第1484号 学位授与年月日:令和5年3月20日; Author: Hidenori Ito, Tomohiro Matsuo, Kensuke Mitsunari, Kojiro Ohba and Yasuyoshi Miyata; Citation: Medicina, 58(6), art. no. 825; 2022; identifier:Nagasaki University (長崎大学), 博士(医学) (2023-03-20)
• Source: fulltext; https://nagasaki-u.repo.nii.ac.jp/?action=repository_action_common_download&item_id=27996&item_no=1&attribute_id=70&file_no=1
• Access Restrictions: インターネット公開
• Rights (production): © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
• Related Material: http://hdl.handle.net/10069/00042119
• Related Material (DOI): 10.3390/medicina58060825
• Data Provider (Database): 国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）; https://irdb.nii.ac.jp
• Original Data Provider (Database): 長崎大学 : 長崎大学学術研究成果リポジトリ